Profile data is unavailable for this security.
About the company
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
- Revenue in USD (TTM)850.00k
- Net income in USD-47.76m
- Incorporated2018
- Employees32.00
- LocationCompass Therapeutics Inc.80 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 500-8099
- Fax+1 (302) 655-5049
- Websitehttps://www.compasstherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nkarta Inc | 0.00 | -110.61m | 176.42m | 159.00 | -- | 0.4095 | -- | -- | -1.87 | -1.87 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -23.59 | -32.39 | -24.86 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 177.48m | 158.00 | -- | 0.6312 | -- | 15.47 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -110.66m | 177.77m | 119.00 | -- | 0.5875 | -- | -- | -2.50 | -2.50 | 0.00 | 7.01 | 0.00 | -- | -- | 0.00 | -51.27 | -- | -57.66 | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 179.23m | 59.00 | -- | 2.16 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Nektar Therapeutics | 93.14m | -168.30m | 184.46m | 137.00 | -- | 3.77 | -- | 1.98 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Fulcrum Therapeutics Inc | 80.87m | -17.91m | 186.58m | 76.00 | -- | 0.6268 | -- | 2.31 | -0.3098 | -0.3098 | 1.29 | 4.77 | 0.2899 | -- | 23.41 | 1,064,092.00 | -6.42 | -50.55 | -6.77 | -55.91 | -- | -- | -22.15 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.76m | 188.50m | 32.00 | -- | 1.36 | -- | 221.76 | -0.3553 | -0.3553 | 0.0063 | 1.01 | 0.0053 | -- | -- | 26,562.50 | -29.93 | -41.75 | -31.25 | -46.41 | -- | -- | -5,618.71 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Zura Bio Ltd | 0.00 | -42.62m | 189.35m | 14.00 | -- | 1.24 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| ADC Therapeutics SA | 70.72m | -212.15m | 191.45m | 273.00 | -- | -- | -- | 2.71 | -2.40 | -2.40 | 0.7742 | -1.78 | 0.1733 | 0.2987 | 3.13 | 259,036.60 | -51.13 | -48.41 | -62.27 | -55.63 | 91.81 | -- | -295.00 | -308.62 | 4.68 | -3.92 | 1.65 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 192.39m | 145.00 | -- | 1.29 | -- | 2.67 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -38.70m | 195.85m | 19.00 | -- | 1.30 | -- | -- | -4.69 | -4.69 | 0.00 | 12.36 | 0.00 | -- | -- | 0.00 | -38.61 | -86.84 | -49.21 | -130.46 | -- | -- | -- | -769.76 | -- | -- | 0.00 | -- | -- | -- | -5.33 | -- | -- | -- |
| XBiotech Inc | 0.00 | -32.66m | 197.71m | 92.00 | -- | 1.03 | -- | -- | -1.07 | -1.07 | 0.00 | 6.30 | 0.00 | -- | -- | 0.00 | -14.86 | 31.88 | -15.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0495 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Quantum-Si Inc | 2.27m | -89.93m | 197.88m | 159.00 | -- | 0.9423 | -- | 87.33 | -0.6334 | -0.6334 | 0.016 | 1.48 | 0.0082 | 0.3423 | 3.05 | 14,251.57 | -32.43 | -- | -34.05 | -- | 51.54 | -- | -3,968.84 | -- | 13.15 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 198.17m | 88.00 | -- | 1.16 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 198.94m | 265.00 | -- | 1.13 | -- | 3.22 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Data as of Nov 21 2024. Currency figures normalised to Compass Therapeutics Inc.'s reporting currency: US Dollar USD
32.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 30 Sep 2024 | 11.13m | 8.09% |
| Blackstone Alternative Asset Management LPas of 30 Sep 2024 | 8.52m | 6.19% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.22m | 4.52% |
| Rock Springs Capital Management LPas of 30 Sep 2024 | 5.63m | 4.09% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.20m | 3.06% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.31m | 1.68% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.86m | 1.36% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 1.84m | 1.34% |
| Tang Capital Management LLCas of 30 Sep 2024 | 1.81m | 1.32% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 1.56m | 1.13% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
